相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies
J. Ailani et al.
EUROPEAN JOURNAL OF NEUROLOGY (2020)
Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
Stewart J. Tepper et al.
CEPHALALGIA (2020)
Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
Raffaele Ornello et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Erenumab: from scientific evidence to clinical practicethe first Italian real-life data
Piero Barbanti et al.
NEUROLOGICAL SCIENCES (2019)
Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies
Andrea Negro et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2019)
The American Headache Society's Position Statement on Integrating New Migraine Treatments into Clinical Practice - Comments
James A. Charles et al.
HEADACHE (2019)
Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
Bianca Raffaelli et al.
JOURNAL OF HEADACHE AND PAIN (2019)
EARLY AUSTRALIAN EXPERIENCE WITH ERENUMAB FOR CHRONIC MIGRAINE
Shuli Cheng et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Current and emerging evidence-based treatment options in chronic migraine: a narrative review
Elio Clemente Agostoni et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
Michel D. Ferrari et al.
LANCET (2019)
The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal
Raffaele Ornello et al.
JOURNAL OF HEADACHE AND PAIN (2019)
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
Simona Sacco et al.
JOURNAL OF HEADACHE AND PAIN (2019)
CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study
Clara Dominguez et al.
HEADACHE (2018)
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
Messoud Ashina et al.
CEPHALALGIA (2018)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
Treatment of chronic migraine with botulinum neurotoxin A. Expert recommendations of the German Migraine and Headache Society
R. Ruscheweyh et al.
NERVENARZT (2018)
Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
Casper Emil Christensen et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Early onset of efficacy with erenumab in patients with episodic and chronic migraine
Todd Schwedt et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
Uwe Reuter et al.
LANCET (2018)
Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis
Zsolt Hepp et al.
CEPHALALGIA (2017)
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Stewart Tepper et al.
LANCET NEUROLOGY (2017)
A Controlled Trial of Erenumab for Episodic Migraine
Peter J. Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long-term Treatment Benifits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy
Simona Guerzoni et al.
FRONTIERS IN NEUROLOGY (2017)
Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab
Maria Adele Giamberardino et al.
JOURNAL OF PAIN RESEARCH (2017)
Adherence to oral migraine-preventive medications among patients with chronic migraine
Zsolt Hepp et al.
CEPHALALGIA (2015)
Insights Into the Mechanism of OnabotulinumtoxinA in Chronic Migraine
Paul L. Durham et al.
HEADACHE (2011)
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program
David W. Dodick et al.
HEADACHE (2010)
Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults
S. Silberstein et al.
CEPHALALGIA (2008)
Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A
KR Aoki
NEUROTOXICOLOGY (2005)
分享论文
